Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PCSK9 Inhibitor Wars: How Does Inclisiran Fit in with Current Monoclonal Antibody Inhibitor Therapy? Considerations for Patient Selection
Natalie Arnold, Wolfgang Köenig
Current Cardiology Reports (2022) Vol. 24, Iss. 11, pp. 1657-1667
Open Access | Times Cited: 28

Showing 1-25 of 28 citing articles:

Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a)
Niki Katsiki, Michal Vráblík, Maciej Banach, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 4, pp. 577-577
Open Access | Times Cited: 37
Beyond statins: New pharmacological targets to decrease LDL-cholesterol and cardiovascular events
Emanuel Raschi, Manuela Casula, Arrigo F.G. Cicero, et al.
Pharmacology & Therapeutics (2023) Vol. 250, pp. 108507-108507
Open Access | Times Cited: 34
PCSK9 inhibition with orally administered NNC0385-0434 in hypercholesterolaemia: a randomised, double-blind, placebo-controlled and active-controlled phase 2 trial
Michael J. Koren, Olivier Descamps, Yoshiki Hata, et al.
The Lancet Diabetes & Endocrinology (2024) Vol. 12, Iss. 3, pp. 174-183
Closed Access | Times Cited: 15
Cost-Effectiveness Analysis of Inclisiran for the Treatment of Primary Hypercholesterolemia or Mixed Dyslipidemia in Singapore
Young‐Hee Lim, Ru San Tan, Kian Keong Poh, et al.
Value in Health Regional Issues (2025), pp. 101067-101067
Closed Access | Times Cited: 1
Translation of genomics into routine cardiological practice: insights from a European Society of Cardiology Cardiovascular Round Table
Stefanie Dimmeler, Leticia Ferri, Paul Nioi, et al.
European Heart Journal (2025)
Closed Access | Times Cited: 1
The formation and consequences of cholesterol-rich deposits in atherosclerotic lesions
Frederick R. Maxfield, Noah Steinfeld, J. Cheng-I
Frontiers in Cardiovascular Medicine (2023) Vol. 10
Open Access | Times Cited: 18
Inclisiran—A Revolutionary Addition to a Cholesterol-Lowering Therapy
Adrianna Dec, Aleksandra Niemiec, Eliza Wojciechowska, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 7, pp. 6858-6858
Open Access | Times Cited: 10
New Oral PCSK9 Inhibitor: “MK-0616”
Zoya Siddiqui, William H. Frishman
Cardiology in Review (2024)
Closed Access | Times Cited: 3
Retrospective Evaluation of LDL-C Levels Following First Treatment With Inclisiran as Part of Secondary Prevention ASCVD Risk Reduction in a Real-World Primary Care Setting
Carl Deaney, Meredith Donaldson, Danielle Reesby, et al.
Journal of Primary Care & Community Health (2024) Vol. 15
Open Access | Times Cited: 3
Efficacy and outcomes of inclisiran in the management of homozygous and heterozygous familial hypercholesterolemia: a systematic review and meta-analysis
Zaraq Khan, Ajeet Singh, Muhammad Rasool, et al.
Annals of Medicine and Surgery (2025) Vol. 87, Iss. 3, pp. 1599-1608
Open Access
Therapeutic PCSK9 targeting: Inside versus outside the hepatocyte?
Alberto Corsini, Henry N. Ginsberg, M. John Chapman
Pharmacology & Therapeutics (2025), pp. 108812-108812
Closed Access
Lipid lowering with inclisiran: a single-center experience from Slovakia
Štefan Tóth, Marianna Vachalcová, Adriana Jarolimkova, et al.
Klinická farmakologie a farmacie (2025) Vol. 39, Iss. 1, pp. 14-21
Open Access
Inhibition of PCSK9 with polypurine reverse hoogsteen hairpins: A novel gene therapy approach
Ester López-Aguilar, Silvia Cecilia Pacheco-Velázquez, Maria Antònia Busquets, et al.
Biochemical Pharmacology (2025), pp. 116976-116976
Open Access
A Real-World Retrospective Analysis of Secondary Prevention Patients Treated with Inclisiran over 27 Months
Carl Deaney, Meredith Donaldson, Agne Meskauskiene
Clinical Medicine Insights Cardiology (2025) Vol. 19
Open Access
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Eligibility and Prescription Rates in Patients Presenting With Recurrent Acute Coronary Syndromes
William B He, Dylan Jape, Shane Nanayakkara, et al.
Heart Lung and Circulation (2024)
Open Access | Times Cited: 2
Hepatocellular carcinoma epi-immunotherapy with polyion complex micelles co-delivering HDAC8 inhibitor and PD-L1 siRNA
Jinhua Zhao, Taiqing Liu, Yinqi Li, et al.
Chemical Engineering Journal (2024), pp. 158138-158138
Closed Access | Times Cited: 2
Chemical constituents from Morus alba with proprotein convertase subtilisin/kexin type 9 expression and secretion inhibitory activity
Hongic Won, Min-Gyung Son, Pisey Pel, et al.
Organic & Biomolecular Chemistry (2023) Vol. 21, Iss. 13, pp. 2801-2808
Closed Access | Times Cited: 5
Efficacy and safety of ongericimab given by prefilled syringe or autoinjector in primary hypercholesterolemia and mixed hyperlipidemia
Zhao Wang, Zhifeng Cheng, Xianyou Ji, et al.
Nutrition Metabolism and Cardiovascular Diseases (2024) Vol. 34, Iss. 9, pp. 2217-2225
Closed Access | Times Cited: 1
Acyclic Triterpenoids from Alpinia katsumadai Seeds with Proprotein Convertase Subtilisin/Kexin Type 9 Expression and Secretion Inhibitory Activity
Chae-Yeong An, Min-Gyung Son, Young‐Won Chin
ACS Omega (2023) Vol. 8, Iss. 36, pp. 32804-32816
Open Access | Times Cited: 3
PCSK9 Targeting in the Management of Hypercholesterolaemia
Constantine E. Kosmas, E Papakonstantinou, Jacqueline Carreño, et al.
EMJ Cardiology (2023), pp. 87-97
Open Access | Times Cited: 3
Percorso diagnostico e terapeutico della dislipidemia nel paziente ad alto rischio cardiovascolare
Elio Venturini, Giancarlo Casolo, Marco Comeglio, et al.
Gazzetta Medica Italiana Archivio per le Scienze Mediche (2024) Vol. 183, Iss. 6
Open Access
Familial Hypercholesterolemia: Pitfalls and Challenges in Diagnosis and Treatment
Natalie Arnold, Wolfgang Köenig
Reviews in Cardiovascular Medicine (2023) Vol. 24, Iss. 8, pp. 236-236
Open Access | Times Cited: 1
Inclisiran
Christie M. Ballantyne, Abdul Mannan Khan Minhas, Carl E. Orringer
Journal of the American College of Cardiology (2023) Vol. 82, Iss. 24, pp. 2262-2264
Closed Access | Times Cited: 1
Optimization of the MACE endpoint composition to increase power in studies of lipid-lowering therapies—a model-based meta-analysis
Alina Volkova, Б. В. Шульгин, Gabriel Helmlinger, et al.
Frontiers in Cardiovascular Medicine (2024) Vol. 10
Open Access
Postmarketing Reports of Incomplete Dosing-Related Complications with Self-Injected PCSK9 Inhibitors: A Descriptive Study and Disproportionality Analysis
Richard H. Woods
BioDrugs (2024) Vol. 38, Iss. 4, pp. 589-600
Closed Access
Page 1 - Next Page

Scroll to top